文献速递膀胱癌与上尿路尿路上皮癌

转移性尿路上皮癌的转移器官趋向性差异治疗反应:随机对照试验的系统综述与网络Meta分析

Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · Eur Urol Oncol · 2023-11-18

该系统综述与网络Meta分析纳入26项随机对照试验共9082例晚期或转移性尿路上皮癌患者,评估不同转移部位的治疗反应差异。结果显示,度伐利尤单抗联合替西木单抗一线治疗在内脏转移患者中总生存优于化疗(HR 0.81,95%CI 0.67-0.98),帕博利珠单抗二线治疗在内脏转移患者中总生存优于化疗(HR 0.75,95%CI 0.60-0.95),阿替利珠单抗二线治疗在肝转移(肿瘤浸润免疫细胞>5%人群)和淋巴结转移患者中总生存优于化疗。作者认为免疫肿瘤治疗按转移部位选择可能对生存有积极影响,但需进一步研究。

要点

  • 度伐利尤单抗联合替西木单抗一线治疗内脏转移患者总生存优于化疗(HR 0.81,95%CI 0.67-0.98)。
  • 帕博利珠单抗二线治疗内脏转移患者总生存优于化疗(HR 0.75,95%CI 0.60-0.95)。
  • 阿替利珠单抗二线治疗肝转移(肿瘤浸润免疫细胞>5%人群)和淋巴结转移患者总生存优于化疗。

核心结论

  • 在晚期或转移性尿路上皮癌中,按转移部位给予免疫肿瘤治疗可能对一线和二线生存结局有积极影响。
  • 作者认为,仍需进一步开展以转移器官趋向性差异反应和可靠肿瘤学结局为重点的研究,以确定这些患者的最佳管理策略。

研究设计与样本

  • 系统综述与网络Meta分析,遵循系统综述和Meta分析优先报告条目声明进行系统检索。
  • 共纳入26项随机对照试验,合计9082例患者,并进行了正式的网络Meta分析。
  • 主要终点为不同转移部位对应的客观缓解率、总生存和无进展生存。

主要发现

  • 度伐利尤单抗联合替西木单抗作为一线全身治疗,在内脏转移患者中总生存显著优于化疗(HR 0.81,95%CI 0.67-0.98)。
  • 帕博利珠单抗作为二线全身治疗,在内脏转移患者中总生存显著优于化疗(HR 0.75,95%CI 0.60-0.95)。
  • 阿替利珠单抗作为二线全身治疗,在肝转移(肿瘤浸润免疫细胞>5%人群)患者中总生存显著优于化疗(HR 0.51,95%CI 0.28-0.96)。
  • 阿替利珠单抗作为二线全身治疗,在淋巴结转移患者中总生存显著优于化疗(HR 0.59,95%CI 0.37-0.96)。

关键数值与推荐

  • 内脏转移患者一线度伐利尤单抗联合替西木单抗对比化疗的总生存HR 0.81(95%CI 0.67-0.98)。
  • 内脏转移患者二线帕博利珠单抗对比化疗的总生存HR 0.75(95%CI 0.60-0.95)。
  • 肝转移(肿瘤浸润免疫细胞>5%人群)患者二线阿替利珠单抗对比化疗的总生存HR 0.51(95%CI 0.28-0.96)。
  • 淋巴结转移患者二线阿替利珠单抗对比化疗的总生存HR 0.59(95%CI 0.37-0.96)。

临床怎么用

  • 作者认为,目前支持按转移部位选择全身治疗以获得肿瘤学获益的证据尚不足以提供推荐。
  • 作者认为,临床医生可仅在充分告知患者最佳治疗决策的讨论中考虑肿瘤器官趋向性。

局限性

  • 作者指出,支持按转移部位选择全身治疗以获得肿瘤学获益的证据尚不够强,不足以提供推荐。
  • 作者指出,仍需进一步开展以转移器官趋向性差异反应和可靠肿瘤学结局为重点的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The optimal therapeutic agent with respect to metastatic sites is unclear in advanced urothelial carcinoma (UC). OBJECTIVE: To investigate the metastatic organotropism differential treatment response in patients with advanced or metastatic UC. EVIDENCE ACQUISITION: A systematic search and network meta-analysis (NMA) was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. The primary endpoints of interest were the objective response rate, overall survival (OS), and progression-free survival with respect to different metastatic sites. EVIDENCE SYNTHESIS: Twenty-six trials comprising 9082 patients met our eligibility criteria, and a formal NMA was conducted. Durvalumab plus tremelimumab as first-line systemic therapy was significantly associated with better OS than chemotherapy in visceral metastasis (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.67-0.98). Pembrolizumab as second-line systemic therapy was significantly associated with better OS than chemotherapy in patients with visceral metastasis (HR 0.75, 95% CI 0.60-0.95). Atezolizumab as second-line systemic therapy was significantly associated with better OS than chemotherapy in patients with liver metastasis (in the population of >5% of tumor-infiltrating immune cells) and lymph node metastasis (HR 0.51, 95% CI 0.28-0.96, and HR 0.59, 95% CI 0.37-0.96, respectively). CONCLUSIONS: Administration of immune-oncology treatments with respect to metastatic sites in patients with advanced or metastatic UC might have a positive impact on survival outcomes in both the first- and the second-line setting. Nevertheless, further investigations focusing on metastatic organotropism differential response with reliable oncological outcomes are needed to identify the optimal management strategy for these patients. PATIENT SUMMARY: Although the supporting evidence for oncological benefits of therapeutic systemic agents with respect to metastatic sites is not yet strong enough to provide a recommendation in advanced or metastatic urothelial carcinoma, clinicians may take into account tumor organotropism only in discussion with the patient fully informed on the optimal treatment decision to be taken.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Kardoust Parizi M, Matsukawa A, Bekku K, et al. Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Eur Urol Oncol. 2023. PMID: 37980251. doi:10.1016/j.euo.2023.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。